

# West Virginia Medicaid Drug Utilization Review Board Minutes

February 24, 2021

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

## **Members:**

K.C. Lovin, PA-C, Chair  
Christopher Terpening, PharmD, PhD, Vice Chair  
C.K. Babcock, PharmD  
Michael Ballow, PharmD  
Chris Booth, PharmD  
Scott Brown, RPh  
Myra Chiang, MD  
Kate Forman, PharmD  
Phillip Galapon, MD  
David Gloss, MD  
Lester Labus, MD  
Michael Lonsinger, PharmD  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS

## **Members Absent:**

none

## **DHHR/BMS Staff:**

Brian Thompson, MS, PharmD, Director of Pharmacy Services  
Priya Shah, PharmD, Drug Utilization Review Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy operations Manager  
Doug Sorvig, Data Analyst  
Gail Goodnight, Rebate Manager  
Jim Becker, MD

## **Contract Staff:**

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)  
Robert Stanton, PharmD, Marshall University  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
Jon Willis, Marshall University  
Eric Sears, RPh, Gainwell  
Jeff Barkin, MD, Change Healthcare  
Ryan Fell, PharmD, Change Healthcare

## **I. INTRODUCTIONS**

- a. K.C. Lovin, PA-C, Chair, welcomed everyone to the Board meeting at 4:00 pm EDT. The DUR Board introduced themselves.

- II. **ARRPOVAL OF MINUTES FROM November 18, 2020 DUR BOARD MEETING**
  - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.
  
- III. **OLD BUSINESS**
  - none
  
- IV. **NEW BUSINESS**
  - a. **Speakers**
    - i. See agenda attachments a-c speaking for Evrysdi
  
  - b. **Updates from January 27, 2021 P & T Committee Meeting**
    - i. Ryan Fell presented the updates from the January 27, 2021 P & T meeting for board review. No changes were requested.
  
  - c. **Proposed Prior-Authorization Criteria. Attachment A**
    - i. Evrysdi – approved as presented with request to revisit at the next meeting
    - ii. Breztri – approved as presented
    - iii. Palforzia – approved as presented
    - iv. Entocort EC, Ortikos – approved as presented
    - v. Lubiprostone – approved as presented
    - vi. Oriahnn – approved as presented
    - vii. Enspryng – approved as presented
    - viii. Analgesics, Narcotics Long-Acting – approved as presented
    - ix. Suboxone policy – approved as presented (nay votes: Galapon & Babcock)
  
- V. **REPORTS – 4<sup>th</sup> Quarter 2021**
  - a. **Gainwell Quarterly Report:** Mr. Sears presented an overview of the 2020 4<sup>th</sup> Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
  - b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the Fourth Quarter 2020. Attachment C
  - c. **Marshall University Coalition:** Dr. Robert Stanton reported on the progress of retro DUR, the lock in program, number of letters sent/returned, and quarterly newsletter. Introduction of special topics to be discussed monthly. Members will vote on topics in order of preference using Qualtrics. Attachment D
  
- VI. **OTHER BUSINESS**
  - a. None
  
- VII. **NEXT MEETING AND ADJOURNMENT**
  - a. The meeting concluded at 5:43 pm EDT.
  - b. The next meeting will be May 26, 2021 (VIRTUAL) from 4:00pm to 6:00pm